- Home
- CUE vs EDAP Comparison
CUE vs EDAP Comparison
Compare CUE & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- EDAP
- Stock Information
- Founded
- CUE 2014
- EDAP 1979
- Country
- CUE United States
- EDAP France
- Employees
- CUE N/A
- EDAP N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CUE Health Care
- EDAP Health Care
- Exchange
- CUE Nasdaq
- EDAP Nasdaq
- Market Cap
- CUE 48.0M
- EDAP 53.8M
- IPO Year
- CUE 2018
- EDAP 1997
- Fundamental
- Price
- CUE $0.67
- EDAP $1.67
- Analyst Decision
- CUE Strong Buy
- EDAP Buy
- Analyst Count
- CUE 3
- EDAP 3
- Target Price
- CUE $3.00
- EDAP $8.50
- AVG Volume (30 Days)
- CUE 278.1K
- EDAP 37.9K
- Earning Date
- CUE 08-13-2025
- EDAP 05-15-2025
- Dividend Yield
- CUE N/A
- EDAP N/A
- EPS Growth
- CUE N/A
- EDAP N/A
- EPS
- CUE N/A
- EDAP N/A
- Revenue
- CUE $7,991,000.00
- EDAP $67,840,467.00
- Revenue This Year
- CUE N/A
- EDAP N/A
- Revenue Next Year
- CUE $23.84
- EDAP N/A
- P/E Ratio
- CUE N/A
- EDAP N/A
- Revenue Growth
- CUE 13.83
- EDAP 3.69
- 52 Week Low
- CUE $0.45
- EDAP $1.26
- 52 Week High
- CUE $1.99
- EDAP $5.46
- Technical
- Relative Strength Index (RSI)
- CUE 48.20
- EDAP 35.49
- Support Level
- CUE $0.65
- EDAP $1.60
- Resistance Level
- CUE $0.88
- EDAP $1.80
- Average True Range (ATR)
- CUE 0.07
- EDAP 0.10
- MACD
- CUE 0.01
- EDAP -0.01
- Stochastic Oscillator
- CUE 39.34
- EDAP 8.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.